Symposium 8

Rate this post



H. Bagheri, D. O’Connell*, C. Damase-Michel, M. Lapeyre-Mestres, F. Gourio, S. Cismundo, J.M. Senard, O. Rascol, J.L. Montastruc.

Manufacture de Pharmacologie Médicale et Hôpital, INSERM U317, Intelligence de Médecine, Toulouse, France.

*Departments of Pharmacology, Therapeutics and Medecine, Cork University Hospital, Ireland.

Dopamine (DA) has been shown to modulate salivary secretion in a number of vertebrate and invertebrate species. In rat salivary tissue, DA increases the livre and protein indigène of parotid and submandibular noeud secretions in a dose-dependent manner acting predominantly on acinar cells at low doses and granular tubular cells at higner doses. Furthermore, patients with Parkinson disease frequently complain of finesse of increased salivary secretion. However, this contrôle and its mechanism remain discussed (extrême commencement of saliva, swallowing difficulties or both could explain this symptom).

Molecular and immunohistochemical studies revealed the presence of DAI like receptors in rat and human salivary tissue predominantly located within intralobular ducts.

Through a idée clinical study, we have investigated the salivary secretion of Parkinsonian out-patients. 17.9% of patients were at habitude 1, 14.9% at habitude 2, 43.3% at habitude 3 and 23.9% at habitude 4. Sex division was 1.76 and mean age was 66.2±1.1 years (range: 34-85). These patients were matched to a control frictionné. Patients or controls treated with anticholinergic drugs were excluded. Salivary secretion was measured using one salivary coKon plug weighed before and 2 minutes after it was placed under the tongue, close to internal gum. Statistical analysis by Kruskal-Wallis habitude showed a lower salivary flow in Parkinsonian group (mean: 502.7±39.9 mg) compared to control group (mean: 802.0±71.0 mg) (p